Zobrazeno 1 - 10
of 48
pro vyhledávání: ''
Autor:
Yuping Dong, Robert Hamlin, Daniel Gaudet, Erik S.G. Stroes, Lesley J. Burgess, Robert Pordy, Nagwa Khilla, Shazia Ali, C. Ebenbichler, Seth J. Baum, Robert S. Rosenson, Vladimir Son
Publikováno v:
New England journal of medicine, 383(24), 2307-2319. Massachussetts Medical Society
Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum tolerated doses, have an increased risk of atherosclerosis. In such patients, the
Autor:
Ken, Okumura, Masaharu, Akao, Tetsuro, Yoshida, Masahito, Kawata, Osamu, Okazaki, Shintaro, Akashi, Kenichi, Eshima, Kimihiko, Tanizawa, Masayuki, Fukuzawa, Takuya, Hayashi, Masahiro, Akishita, Gregory Y H, Lip, Takeshi, Yamashita
Publikováno v:
Okumura, K, Akao, M, Yoshida, T, Kawata, M, Okazaki, O, Akashi, S, Eshima, K, Tanizawa, K, Fukuzawa, M, Hayashi, T, Akishita, M, Lip, G Y H & Yamashita, T 2020, ' Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation ', New England Journal of Medicine, vol. 383, no. 18, pp. 1735-1745 . https://doi.org/10.1056/NEJMoa2012883
BACKGROUND: Implementation of appropriate oral anticoagulant treatment for the prevention of stroke in very elderly patients with atrial fibrillation is challenging because of concerns regarding bleeding. METHODS: We conducted a phase 3, multicenter,
Autor:
Kolb, Martin, Raghu, Ganesh, Wells, Athol U, Behr, Jürgen, Richeldi, Luca, Schinzel, Birgit, Quaresma, Manuel, Stowasser, Susanne, INSTAGE Trial Investigators, Benjamin Bondue, Bondue, Benjamin, Martinez, Fernando J
Publikováno v:
The New England journal of medicine, 379 (18
Background Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup analysis of a previously published trial suggested that sildenafil may provide benefits regarding oxygenation, gas exchange as measured by the diffusio
Autor:
Lucie Blondeau, Mylène Provencher, Olivier F. Bertrand, Aldo P. Maggioni, José López-Sendón, Jean-Claude Tardif, François Roubille, Simon Kouz, Wolfgang Koenig, Marie-Pierre Dubé, Rafael Diaz, Andreas Orfanos, Reda Ibrahim, Denis Angoulvant, Petr Ostadal, Fausto J. Pinto, Jean Grégoire, Ghassan S. Kiwan, Marie-Claude Guertin, David D. Waters, Marc-André Lavoie, David Rhainds, Colin Berry, Habib Gamra, Philippe L. L’Allier
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
New England Journal of Medicine
New England Journal of Medicine, 2019, ⟨10.1056/NEJMoa1912388⟩
The New England journal of medicine, vol 381, iss 26
New England Journal of Medicine, Massachusetts Medical Society, 2019, ⟨10.1056/NEJMoa1912388⟩
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
New England Journal of Medicine
New England Journal of Medicine, 2019, ⟨10.1056/NEJMoa1912388⟩
The New England journal of medicine, vol 381, iss 26
New England Journal of Medicine, Massachusetts Medical Society, 2019, ⟨10.1056/NEJMoa1912388⟩
Copyright © 2019 Massachusetts Medical Society. All rights reserved.
Background: Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinfl
Background: Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinfl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::245444c6724cffe5dc69b81d63e21083
https://eprints.gla.ac.uk/204890/1/204890.pdf
https://eprints.gla.ac.uk/204890/1/204890.pdf
Autor:
Stephane OUDARD, David Olmos Hidalgo, María J. Ribal, Tomasz Drewa, ARANZAZU GONZALEZ-DEL-ALBA, Marcin Słojewski, Susan Ellard, Louis Lacombe, PABLO MAROTO REY, Javier Angulo, Adel Izmailov, Gwenaelle Gravis, Lisa Horvath, Boris Hadaschik, Ernesto Sanchez Sanchez, Florence Joly, Emmanuelle Bompas, Anders Kjellman, Hakim MAHAMMEDI, Arnauld VILLERS, Jose Luis Perez-Gracia, Carlos Ferrer Albiach
Publikováno v:
The New England Journal of Medicine, 378, 15, pp. 1408-1418
Poulsen, M H & SPARTAN Investigators 2018, ' Apalutamide treatment and metastasis-free survival in prostate cancer ', New England Journal of Medicine, vol. 378, no. 15, pp. 1408-1418 . https://doi.org/10.1056/NEJMoa1715546
The New England Journal of Medicine, 378, 1408-1418
Poulsen, M H & SPARTAN Investigators 2018, ' Apalutamide treatment and metastasis-free survival in prostate cancer ', New England Journal of Medicine, vol. 378, no. 15, pp. 1408-1418 . https://doi.org/10.1056/NEJMoa1715546
The New England Journal of Medicine, 378, 1408-1418
Contains fulltext : 193640.pdf (Publisher’s version ) (Open Access) BACKGROUND: Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in me
Autor:
Maria C. Cid, Bhaskar Dasgupta, Elisabeth Brouwer, Sophie Dimonaco, Georg Schett, Sebastian Unizony, John H. Stone, Hendrik Schulze-Koops, Neil Collinson, Robert Spiera, Juergen Rech, Micki Klearman, Martin Aringer, Daniel Engelbert Blockmans, Carlo Salvarani, Katie Tuckwell
Publikováno v:
New England Journal of Medicine, 377(4), 317-328. MASSACHUSETTS MEDICAL SOC
BACKGROUND: Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of glucocorticoids is associated with side effects. The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on the rates of relaps
Autor:
Deepak L. Bhatt, Sangeeta R. Kashyap, Rishi P. Singh, John P. Kirwan, Kathy Wolski, Philip R. Schauer, Steven E. Nissen, Stacy A. Brethauer, Claire E. Pothier, Sankar D. Navaneethan, Ali Aminian
Publikováno v:
New England Journal of Medicine. 376:641-651
Long-term results from randomized, controlled trials that compare medical therapy with surgical therapy in patients with type 2 diabetes are limited.We assessed outcomes 5 years after 150 patients who had type 2 diabetes and a body-mass index (BMI; t
Autor:
Strosberg, J, El Haddad, G, Wolin, E, Hendifar, A, Yao, J, Chasen, B, Mittra, E, Kunz, Pl, Kulke, Mh, Jacene, H, Bushnell, D, O'Dorisio, Tm, Baum, Rp, Kulkarni, Hr, Caplin, M, Lebtahi, R, Hobday, T, Delpassand, E, Van Cutsem, E, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Öberg, K, Lopera Sierra, M, Santoro, P, Thevenet, T, Erion, Jl, Ruszniewski, P, Kwekkeboom, D, Krenning, E, Ansquer, C, Baudin, E, Courbon, F, Giammarile, F, Taieb, D, Scheidhauer, K, Weber, M, Bodei, L, Brianzoni, E, DELLE FAVE, Gianfranco, Chiara Grana, M, Mariani, G, Rindi, G, Severi, S, Azevedo, I, Sundin, A, Al‐nahhas, A, Freemantle, N, Grossman, A, Manoharan, P, Anthony, L, Benson, Ab, Garbus, S, Kulke, M, Kvols, L, Metz, D, Morse, M, Schipper, M, Yao, J.
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Strosberg, J, El-Haddad, G, Wolin, E, Hendifar, A, Yao, J, Chasen, B, Mittra, E, Kunz, P L, Kulke, M H, Jacene, H, Bushnell, D, O'Dorisio, T M, Baum, R P, Kulkarni, H R, Caplin, M, Lebtahi, R, Hobday, T, Delpassand, E, Van Cutsem, E, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Öberg, K, Lopera Sierra, M, Santoro, P, Thevenet, T, Erion, J L, Ruszniewski, P, Kwekkeboom, D, Krenning, E 2017, ' Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors ', New England Journal of Medicine, vol. 376, no. 2, pp. 125-135 . https://doi.org/10.1056/NEJMoa1607427
New England Journal of Medicine, 376(2), 125-135. Massachussetts Medical Society
Recercat. Dipósit de la Recerca de Catalunya
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Universidad de Barcelona
Strosberg, J, El-Haddad, G, Wolin, E, Hendifar, A, Yao, J, Chasen, B, Mittra, E, Kunz, P L, Kulke, M H, Jacene, H, Bushnell, D, O'Dorisio, T M, Baum, R P, Kulkarni, H R, Caplin, M, Lebtahi, R, Hobday, T, Delpassand, E, Van Cutsem, E, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Öberg, K, Lopera Sierra, M, Santoro, P, Thevenet, T, Erion, J L, Ruszniewski, P, Kwekkeboom, D, Krenning, E 2017, ' Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors ', New England Journal of Medicine, vol. 376, no. 2, pp. 125-135 . https://doi.org/10.1056/NEJMoa1607427
New England Journal of Medicine, 376(2), 125-135. Massachussetts Medical Society
Recercat. Dipósit de la Recerca de Catalunya
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Background: Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of
Autor:
Jørgen, Vestbo, David, Leather, Nawar, Diar Bakerly, John, New, J Martin, Gibson, Sheila, McCorkindale, Susan, Collier, Jodie, Crawford, Lucy, Frith, Catherine, Harvey, Henrik, Svedsater, Ashley, Woodcock, S, Kwok
Publikováno v:
Vestbo, J, Leather, D, Bakerly, N D, New, J, Gibson, M, Mccorkindale, S, Collier, S, Crawford, J, Frith, L, Harvey, C, Svedsater, H & Woodcock, A 2016, ' Effectiveness of Fluticasone Furoate/Vilanterol in COPD in clinical practice ', The New England Journal of Medicine, vol. 375, pp. 1253-1260 . https://doi.org/10.1056/NEJMoa1608033
Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials involving groups of patients who were selected on the basis of restricted entry criteria. There is a need for randomized trials t
Autor:
Barbara Sleight, M. Luisa Paccagnella, Wendy Stock, Erik Vandendries, Susan O'Brien, Matthias Stelljes, Nicola Gökbuget, Daniel J. DeAngelo, Tao Wang, Giovanni Martinelli, Kongming Wang, Hagop M. Kantarjian, Michaela Liedtke, Anjali S. Advani
Publikováno v:
New England Journal of Medicine. 375:740-753
The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients with relapsed or refractory a